vs

Side-by-side financial comparison of NORWOOD FINANCIAL CORP (NWFL) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

NORWOOD FINANCIAL CORP is the larger business by last-quarter revenue ($23.5M vs $12.5M, roughly 1.9× Avidity Biosciences, Inc.). NORWOOD FINANCIAL CORP runs the higher net margin — 31.7% vs -1398.3%, a 1430.1% gap on every dollar of revenue. On growth, NORWOOD FINANCIAL CORP posted the faster year-over-year revenue change (1112.9% vs 434.0%). NORWOOD FINANCIAL CORP produced more free cash flow last quarter ($29.2M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 18.5%).

First Financial Bancorp is a regional bank headquartered in Cincinnati, Ohio, with its operations centers in the northern Cincinnati suburb of Springdale, and Greensburg, Indiana. Founded in 1863, First Financial has the sixth oldest national bank charter and has 131 locations throughout Ohio, Indiana, Kentucky, and Illinois. First Financial acquired Irwin Financial Corp and its subsidiaries through a government assisted transaction on September 18, 2009.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

NWFL vs RNA — Head-to-Head

Bigger by revenue
NWFL
NWFL
1.9× larger
NWFL
$23.5M
$12.5M
RNA
Growing faster (revenue YoY)
NWFL
NWFL
+678.8% gap
NWFL
1112.9%
434.0%
RNA
Higher net margin
NWFL
NWFL
1430.1% more per $
NWFL
31.7%
-1398.3%
RNA
More free cash flow
NWFL
NWFL
$186.1M more FCF
NWFL
$29.2M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
18.5%
NWFL

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
NWFL
NWFL
RNA
RNA
Revenue
$23.5M
$12.5M
Net Profit
$7.4M
$-174.4M
Gross Margin
Operating Margin
39.9%
-1513.5%
Net Margin
31.7%
-1398.3%
Revenue YoY
1112.9%
434.0%
Net Profit YoY
158.8%
-117.0%
EPS (diluted)
$0.82
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NWFL
NWFL
RNA
RNA
Q4 25
$23.5M
Q3 25
$23.0M
$12.5M
Q2 25
$21.3M
$3.8M
Q1 25
$20.2M
$1.6M
Q4 24
$1.9M
$3.0M
Q3 24
$18.2M
$2.3M
Q2 24
$17.1M
$2.0M
Q1 24
$16.7M
$3.5M
Net Profit
NWFL
NWFL
RNA
RNA
Q4 25
$7.4M
Q3 25
$8.3M
$-174.4M
Q2 25
$6.2M
$-157.3M
Q1 25
$5.8M
$-115.8M
Q4 24
$-12.7M
$-102.3M
Q3 24
$3.8M
$-80.4M
Q2 24
$4.2M
$-70.8M
Q1 24
$4.4M
$-68.9M
Operating Margin
NWFL
NWFL
RNA
RNA
Q4 25
39.9%
Q3 25
45.9%
-1513.5%
Q2 25
36.7%
-4448.7%
Q1 25
36.1%
-8360.9%
Q4 24
-830.2%
-4069.6%
Q3 24
26.6%
-4200.9%
Q2 24
31.2%
-4040.4%
Q1 24
33.5%
-2178.6%
Net Margin
NWFL
NWFL
RNA
RNA
Q4 25
31.7%
Q3 25
36.3%
-1398.3%
Q2 25
29.1%
-4089.3%
Q1 25
28.6%
-7360.0%
Q4 24
-654.1%
-3439.5%
Q3 24
21.1%
-3441.7%
Q2 24
24.6%
-3461.8%
Q1 24
26.5%
-1943.4%
EPS (diluted)
NWFL
NWFL
RNA
RNA
Q4 25
$0.82
Q3 25
$0.89
$-1.27
Q2 25
$0.67
$-1.21
Q1 25
$0.63
$-0.90
Q4 24
$-1.57
$-0.80
Q3 24
$0.48
$-0.65
Q2 24
$0.52
$-0.65
Q1 24
$0.55
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NWFL
NWFL
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$242.2M
$1.9B
Total Assets
$2.4B
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NWFL
NWFL
RNA
RNA
Q4 25
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Stockholders' Equity
NWFL
NWFL
RNA
RNA
Q4 25
$242.2M
Q3 25
$234.9M
$1.9B
Q2 25
$225.4M
$1.2B
Q1 25
$220.7M
$1.3B
Q4 24
$213.5M
$1.4B
Q3 24
$195.7M
$1.5B
Q2 24
$182.2M
$1.2B
Q1 24
$181.2M
$830.9M
Total Assets
NWFL
NWFL
RNA
RNA
Q4 25
$2.4B
Q3 25
$2.4B
$2.1B
Q2 25
$2.4B
$1.4B
Q1 25
$2.4B
$1.5B
Q4 24
$2.3B
$1.6B
Q3 24
$2.3B
$1.6B
Q2 24
$2.2B
$1.3B
Q1 24
$2.3B
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NWFL
NWFL
RNA
RNA
Operating Cash FlowLast quarter
$34.0M
$-156.2M
Free Cash FlowOCF − Capex
$29.2M
$-156.9M
FCF MarginFCF / Revenue
124.7%
-1257.6%
Capex IntensityCapex / Revenue
20.1%
5.7%
Cash ConversionOCF / Net Profit
4.56×
TTM Free Cash FlowTrailing 4 quarters
$50.8M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NWFL
NWFL
RNA
RNA
Q4 25
$34.0M
Q3 25
$9.3M
$-156.2M
Q2 25
$6.8M
$-199.7M
Q1 25
$9.1M
$-124.8M
Q4 24
$22.8M
$-99.9M
Q3 24
$4.6M
$-65.6M
Q2 24
$9.1M
$-65.0M
Q1 24
$4.3M
$-70.4M
Free Cash Flow
NWFL
NWFL
RNA
RNA
Q4 25
$29.2M
Q3 25
$8.3M
$-156.9M
Q2 25
$5.1M
$-203.0M
Q1 25
$8.2M
$-128.6M
Q4 24
$19.7M
$-103.8M
Q3 24
$4.1M
$-67.3M
Q2 24
$8.6M
$-65.5M
Q1 24
$3.7M
$-71.3M
FCF Margin
NWFL
NWFL
RNA
RNA
Q4 25
124.7%
Q3 25
36.2%
-1257.6%
Q2 25
23.8%
-5277.1%
Q1 25
40.4%
-8174.3%
Q4 24
1017.6%
-3491.0%
Q3 24
22.3%
-2881.8%
Q2 24
50.0%
-3204.6%
Q1 24
22.1%
-2012.3%
Capex Intensity
NWFL
NWFL
RNA
RNA
Q4 25
20.1%
Q3 25
4.5%
5.7%
Q2 25
7.9%
86.9%
Q1 25
4.6%
238.6%
Q4 24
161.7%
131.7%
Q3 24
3.1%
72.9%
Q2 24
3.1%
26.0%
Q1 24
3.3%
25.8%
Cash Conversion
NWFL
NWFL
RNA
RNA
Q4 25
4.56×
Q3 25
1.12×
Q2 25
1.09×
Q1 25
1.58×
Q4 24
Q3 24
1.21×
Q2 24
2.16×
Q1 24
0.96×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons